-
Destiny Pharma hails 'positive dataset' for XF-73 Dermal
31 Jan 2024 09:08 GMT
… work being carried out on XF-73 Dermal, which has delivered a … on the potential toxicity of XF-73 Dermal applied to broken skin … the preclinical safety study in XF-73 Dermal and I am delighted … these results, we can move XF-73 Dermal into the clinic with …
-
Destiny Pharma Shares Rise on Positive Data for XF-73 Drug
17 Oct 2023 08:19 GMT
… on its leading antibacterial drug, XF-73, showed its effectiveness against all …
-
Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73), Against Antibiotic-Resistant Bacteria in Mouse Superficial Skin Infection Models
25 Jul 2023 06:43 GMT
… proprietary, synthetic dicationic porphyrin drug, XF-73 (exeporfinium chloride). Preliminary in vitro … in vitro activity of XF-73, indicating that XF-73 has excellent bactericidal … following exposure to XF-73. TEM images show that XF-73 initially disrupts …
-
Destiny Pharma says XF-73 now "very well positioned" for a...
18 Apr 2023 12:50 GMT
… partner for its lead asset, XF-73, a nasal gel that decolonizes …
-
Destiny Pharma looking to move on to phase III with XF-73 nasal gel
24 Mar 2023 16:51 GMT
… ;s new nasal gel, called XF-73, in the US journal …
-
Destiny Pharma’s XF-73 dermal infection project advances to safety study
16 Nov 2022 05:58 GMT
… News! » Destiny Pharma’s XF-73 dermal infection project advances to … started for Destiny Pharma’s XF-73 dermal formulation.
The company … future clinical development of XF-73 Dermal in serious wound … progress of our novel XF-73 Dermal infection program, which …
-
Destiny Pharma Updates On Phase 2B Clinical Study Of XF-73
27 Jul 2020 08:09 GMT
-
Destiny Pharma’s XF-73 can enhance two widely used antibiotics,...
07 Jul 2022 07:16 GMT
… threatening lung bacterial infections, XF-73 enhanced polymyxin B potency … foot ulcers (DFUs), XF-73 was found to enhance … DFU infections by using XF-73 alongside established antibacterial drugs. …
“The addition of XF-73 significantly enhances the potency …
-
BRIEF-Destiny Pharma Says On Track To Deliver Phase 2B Headline Data In H2 2019 For Xf-73
12 Apr 2018 07:33 GMT
… H2 2019 FOR LEAD ASSET, XF-73, A NOVEL ANTI-MICROBIAL
* FY …
-
BRIEF-Destiny Pharma Says FDA Accepted INDA For Xf-73
26 Feb 2018 07:58 GMT
Feb 26 (Reuters) - Destiny Pharma Plc:
* ANNOUNCES THAT US FDA ACCEPTED AN INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR COMPANY‘S LEAD CLINICAL DRUG CANDIDATE, XF-73 Source text for Eikon: Further company coverage:
About
© 1995-2025